I. UNIFORM FORMULARY REVIEW PROCESS

In accordance with 10 United States Code § 1074g, as implemented by 32 Code of Federal Regulations 199.21, the Department of Defense (DoD) Pharmacy and Therapeutics (P&T) Committee is responsible for developing the Uniform Formulary (UF). Recommendations to the Director, Defense Health Agency (DHA) or their designee, on formulary or complete exclusion status, prior authorizations (PAs), pre-authorizations, and the effective date for a drug’s change from formulary to nonformulary (NF) or to complete exclusion status are received from the Uniform Formulary Beneficiary Advisory Panel (UF BAP), which must be reviewed by the Director or their designee before making a final decision.

II. UF DRUG CLASS REVIEWS—MIGRAINE AGENTS – CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONIST PROPHYLAXIS SUBCLASS

P&T Comments

A. Migraine Agents – Calcitonin Gene-Related Peptide (CGRP) Antagonist Prophylaxis Subclass—Relative Clinical Effectiveness Conclusion

The P&T Committee evaluated the relative clinical effectiveness of the injectable CGRP antagonists. The drugs in the subclass include erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality). The products are administered once monthly for prevention of episodic and chronic migraine. Emgality has an additional formulation approved for treating cluster headache. The class was previously reviewed for formulary placement in February 2019.

The P&T Committee concluded (19 for, 0 opposed, 0 abstained, 1 absent) the following:

CGRP antagonists vs. oral preventive therapies

- The 2021 American Headache Society consensus statement encourages use of oral medications including antiepileptics (e.g., valproate, topiramate), beta-blockers (e.g., metoprolol, propranolol) and antidepressants (e.g., amitriptyline, nortriptyline) as first-line treatment options for migraine headache prevention. Injectable CGRP antagonists are recommended after trials of two different oral preventive medications administered at target therapeutic doses for a minimum of 8 weeks.

- There was no new data to change the conclusion from a 2018 network meta-analysis that the evidence is inadequate to distinguish the net health benefit
between treatment with the CGRP inhibitors versus oral preventive therapies (e.g., amitriptyline, topiramate, or propranolol).

**CGRP antagonist vs. CGRP antagonist**

- Although there are still no published head-to-head trials comparing erenumab, fremanezumab, or galcanezumab, there does not appear to be clinically relevant differences in efficacy, based on indirect comparisons from network-meta-analyses for episodic and chronic migraine.
- The 2018 network meta-analysis evaluated the reduction in monthly migraine days for preventive treatment and concluded the three injectable CGRP medications had similar effectiveness and are more effective than the oral CGRPs (*Note that the oral CGRPs Qulipta, Nurtec ODT and Ubrelvy were not included in this class review.*)

**Safety**

- The CGRP antagonists have a relatively mild side effect profile, with injection site reactions the most commonly reported adverse event. Injection site reactions occurred at an incidence of 5.6% with Aimovig, 18%-23% with Emgality, and 45% with Ajovy.
- A 2023 network meta-analysis concluded the following:
  - Compared to Emgality, treatment with Ajovy has a higher odds ratio for serious adverse effects and treatment-emergent adverse effects. No significant differences were noted in serious adverse events between injectable CGRP treatments and placebo.
  - Ajovy and Emgality showed greater odds of injection site erythema, induration, and pruritus, while Aimovig and Ajovy had higher odds of injection site pain. Ajovy also showed higher odds of diarrhea, and Aimovig had greater odds of constipation, compared to placebo.
  - Overall, the meta-analysis concluded that monoclonal antibodies targeting the calcitonin gene-related peptide pathway are a safe and well-tolerated option for migraine prevention.
- There is limited long term efficacy and safety with chronic use. The five-year extension studies for Aimovig report no significant cardiovascular concerns.

**Individual Product Characteristics**

- **erenumab (Aimovig)** is available in two dosages, 70 mg and 140 mg. It is unclear whether the two doses differ in efficacy or safety. Advantages include publication of a five-year efficacy and safety extension study, fewer reported adverse effects, and availability of both a prefilled syringe and autoinjector, however the prefilled syringe contains latex. Aimovig is stable at room temperature for up to 7 days.
- **fremanezumab (Ajovy)** is the only CGRP inhibitor approved for quarterly dosing in addition to monthly dosing, however administration of three pens at
the same time is required. Ajovy is available in both a prefilled syringe and autoinjector. Disadvantages include the high rate of injection site reactions, and stability at room temperature for only one day.

- **galcanezumab (Emgality)** requires a loading dose, administered as two pens at the same time, however it has a faster onset of action compared to the other drugs. One other advantage is stability at room temperature for up to 7 days. It is the only injectable CGRP with an additional indication for acute cluster headache. Emgality has a higher rate of injection site irritation than Aimovig.

**Overall Clinical Conclusion**

- Overall, there was no new data to substantially change the clinical effectiveness conclusion from the February 2019 class review.

- There is a high degree of interchangeability between the CGRP antagonists. However, there remains uncertainty regarding the long-term efficacy and safety of this drug class.

- At least one injectable CGRP inhibitor is required on the formulary to meet the needs of the majority of Military Health System (MHS) beneficiaries with chronic or episodic migraine headache.

**B. Migraine Agents – CGRP Antagonist Prophylaxis Subclass—Relative Cost-Effectiveness Conclusion**

The P&T Committee reviewed the solicited bids from manufacturers and conducted a cost minimization analysis (CMA), budget impact analysis (BIA), and sensitivity analysis. The P&T Committee concluded (20 for, 0 opposed, 0 abstained, 0 absent) the following:

- CMA results showed that erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality) were all cost effective.

- A BIA and a sensitivity analysis were performed to evaluate the potential impact of designating selected agents as formulary, NF, or completely excluded on the UF. BIA results showed that designating the injectable CGRP agents in accordance with the formulary recommendation below demonstrated significant cost avoidance to the MHS.

**C. Migraine Agents – CGRP Antagonist Prophylaxis Subclass—UF Recommendation**

The P&T Committee recommended (18 for, 2 opposed, 0 abstained, 0 absent) the following for the CGRP Antagonist Prophylaxis agents, as outlined below, based on clinical and cost-effectiveness.

**Chronic and Episodic Migraine**

- UF and step-preferred
- galcanezumab injection 120 mg (Emgality) – moves from UF to UF and step-preferred
- UF and non-step-preferred
  - fremanezumab injection (Ajovy) – moves from UF to UF and non-step-preferred
  - erenumab injection (Aimovig) – moves from UF to UF and non-step-preferred
- Note that for Ajovy and Aimovig, a trial of Emgality 120 mg is required first in new users.
- NF - none
- Complete Exclusion - none

**Cluster Headache**

- UF
  - galcanezumab injection 100 mg (Emgality) – moves from NF to UF (not part of the step therapy for chronic and episodic migraine)
  - NF - none
  - Complete exclusion - none

**D. Migraine Agents – CGRP Antagonist Prophylaxis Subclass—Manual PA Criteria**

Current PA criteria require a trial of standard oral preventive therapies for migraine headache first (antiepileptic medications, beta blockers, or antidepressants), consistent with the American Headache Society Consensus Statement.

The P&T Committee recommended (20 for, 0 opposed, 0 abstained, 0 absent) updates to the current manual PA criteria. The PA for Emgality 120 mg was removed, based on cost effectiveness. The PAs for Aimovig and Ajovy were updated to require a trial of Emgality 120 mg (the new step-preferred agent) in new users, unless the patient has a contraindication, adverse event, or therapeutic failure with Emgality 120 mg. Only new users will be affected by the step-therapy requirements. No changes were recommended for the existing PA criteria for the Emgality 100 mg formulation for cluster headache.

The Manual PA criteria is as follows:

1. **erenumab (Aimovig), fremanezumab (Ajovy)**
   
   **Changes from the November 2023 meeting are in BOLD and strikethrough.**

   Manual PA criteria applies to all new users of Aimovig and Ajovy
   
   - Provider acknowledges that Emgality 120 mg is the DoD’s preferred injectable CGRP inhibitor and is available without a PA.
• Patient has tried and failed Emgality 120 mg OR
• Patient has experienced an adverse reaction to Emgality 120 mg that is not expected to occur with Aimovig or Ajovy OR
• Patient has a contraindication to Emgality 120 mg
• Patient is 18 years of age or older
• Patient is not pregnant
• The drug is prescribed by or in consultation with a neurologist
• The patient also meets one of the following:
  ▪ Patient has episodic migraines at a rate of 4 to 7 migraine days per month for 3 months and has at least moderate disability shown by Migraine Disability Assessment (MIDAS) Test score > 11 or Headache Impact Test-6 (HIT-6) score > 50 OR
  ▪ Patient has episodic migraines at a rate a migraine diagnosis with of at least 8 migraine days per month for 3 months OR
  ▪ Patient has a diagnosis of chronic migraine
• Patient has a contraindication to, intolerability to, or has failed a 2-month trial of at least ONE drug from TWO of the following migraine prophylactic drug classes:
  ▪ Prophylactic antiepileptic medications: valproate, divalproic acid, topiramate
  ▪ Prophylactic beta-blocker medications: metoprolol, propranolol, atenolol, nadolol, timolol
  ▪ Prophylactic antidepressants: amitriptyline, duloxetine, nortriptyline, venlafaxine
• Concurrent use with other CGRP inhibitors (e.g., Aimovig, Ajovy, Emgality) is not allowed

Non-FDA-approved uses are NOT approved
PA expires after 6 months

Renewal Criteria: Note that initial TRICARE PA approval is required for renewal. Coverage will be approved indefinitely for continuation of therapy if one of the following apply:
• The patient has had a reduction in mean monthly headache days of ≥ 50% relative to the pretreatment baseline (as shown by patient diary documentation or healthcare provider attestation) OR
• The patient has shown a clinically meaningful improvement in ANY of the following validated migraine-specific patient-reported outcome measures:
  ▪ Migraine Disability Assessment (MIDAS)
    ▪ Reduction of ≥ 5 points when baseline score is 11–20
    ▪ Reduction of ≥ 30% when baseline score is > 20
- Headache Impact Test (HIT-6)
  - Reduction of ≥ 5 points
- Migraine Physical Functional Impact Diary (MPFID)
  - Reduction of ≥ 5 points

2. **galcanezumab 100 mg injection (Emgality)**

   Changes from the November 2023 meeting are in **BOLD and strikethrough**.

   Note that this PA applies to the Emgality 100 mg cluster headache formulation. **The Emgality 120 mg migraine prophylaxis formulation is available without a PA. The Emgality 120 mg migraine prophylaxis indication PA criteria is on a separate form.**

   Manual PA criteria apply to all new users of Emgality at a dosage of 300 mg/month for episodic cluster headaches.
   - Patient is 18 years of age or older
   - Patient is not pregnant
   - The drug must be prescribed by or in consultation with a neurologist
   - Patient has a diagnosis of episodic cluster headaches
   - Patient has a contraindication to, intolerability to, or has failed an adequate trial of verapamil, topiramate, or lithium
   - Concurrent use with other CGRP inhibitors (e.g., Aimovig, Emgality 120 mg, Ajovy) is not allowed

   Non-FDA-approved uses, including for migraine prophylaxis, chronic cluster headache, medication overuse headache, etc., are not approved

   PA expires after 6 months

   **Renewal Criteria:** Note that initial TRICARE PA approval is required for renewal. Coverage will be approved indefinitely for continuation of therapy if there is a clinically appropriate reduction in weekly attacks (≥ 50% reduction in weekly cluster headache attack frequency) during an episode as reported by the patient.

   **E. Migraine Agents – CGRP Antagonist Prophylaxis Subclass—UF, PA, and Implementation Period**

   The P&T Committee recommended (20 for, 0 opposed, 0 abstained, 0 absent) an effective date of the first Wednesday 30 days after the signing of the minutes in all points of service, with the exception that the current PA for Emgality 120 mg will be removed 2 weeks after signing of the minutes.
III. UF DRUG CLASS REVIEWS—MIGRAINE AGENTS —CGRP ANTAGONIST PROPHYLAXIS SUBCLASS

**UF BAP Comments**

**A. Migraine Agents – CGRP Antagonist Prophylaxis Subclass—UF Recommendation**

The P&T Committee recommended formulary status as discussed above.

*Chronic and Episodic Migraine*
- UF and step-preferred
  - Emgality 120 mg – *moves from UF to UF and step-preferred*
- UF and non-step-preferred
  - Ajovy – *moves from UF to UF and non-step-preferred*
  - Aimovig – *moves from UF to UF and non-step-preferred*
- NF - none
- Complete Exclusion - none

*Cluster Headache*
- UF
  - Emgality 100 mg – *moves from NF to UF*
- NF - none
- Complete Exclusion - none

**UF BAP Comments**

*Concur*:

*Non-Concur*:

*Abstain*:

*Absent*:

---

**B. Migraine Agents –CGRP Antagonist Prophylaxis Subclass—Manual PA Criteria**

The P&T Committee recommended manual PA criteria as outlined above.

**UF BAP Comments**

*Concur*:

*Non-Concur*:

*Abstain*:

*Absent*:
C. Migraine Agents – CGRP Antagonist Prophylaxis Subclass—UF, PA, and Implementation Period

The P&T Committee recommended an effective date of the first Wednesday 30 days after signing of the minutes in all points of service and removing the PA for Emgality 120 mg two weeks after signing of the minutes.

_UF BAP Comments_

Concur:    Non-Concur:    Abstain:    Absent:

IV. UF DRUG CLASS REVIEWS—NEUROLOGICAL AGENTS MISCELLANEOUS - MOVEMENT DISORDERS

_P&T Comments_

A. Neurological Agents Miscellaneous - Movement Disorders—Relative Clinical Effectiveness Analysis and Conclusion

The P&T Committee evaluated the relative clinical effectiveness of the Movement Disorder subclass, which includes the vesicular monoamine transporter type 2 (VMAT2) inhibitors. The drugs evaluated were tetrabenazine (Xenazine, generics), deutetrabenazine immediate release and extended release (Austedo IR and XR), and valbenazine (Ingrezza). All four drugs are approved for treating Huntington’s disease chorea. Deutetrabenazine and valbenazine are also approved for tardive dyskinesia, while tetrabenazine is used off-label for this indication. The class was last reviewed for formulary status in November 2018; since then, there are now overlapping indications for deutetrabenazine and valbenazine.

The clinical review focused on available published trials, clinical practice guidelines, meta-analyses, and systematic reviews.

The P&T Committee concluded (19 for, 0 opposed, 0 abstained, 1 absent) the following:

**Guidelines**

- *Huntington’s disease chorea:* Professional clinical practice guidelines from the 2019 International Guideline for Treatment of Huntington’s Disease from the European Huntington’s Disease Network recommend considering treatment when the disorder causes patient distress or discomfort. Tetrabenazine is mentioned as a first-line treatment option, with deutetrabenazine considered as an alternative to tetrabenazine. Austedo XR and Ingrezza were recently FDA-approved for Huntington’s disease chorea in 2023 and are not mentioned in this publication.

- *Tardive dyskinesia:* The 2019 Canadian Journal of Psychiatry treatment recommendations for tardive dyskinesia state that all antipsychotic medications are...
associated with risk. Recommendations include considering switching from a first-generation antipsychotic to a second-generation (atypical) antipsychotic. For the VMAT2 inhibitors, recommendations are specified for valbenazine and deutetetabenazine (Evidence I+, Grade A), and tetrabenazine (Evidence I-, Grade B).

**Efficacy**

- **There are currently no head-to-head trials comparing Xenazine, Austedo, or Ingrezza for tardive dyskinesia or Huntington's disease chorea.**

  - **Huntington's disease chorea:** An indirect efficacy analysis of individual placebo-controlled clinical trials of Xenazine, Austedo IR, and Ingrezza was reviewed. Each trial demonstrated statistically significant and similar magnitude of reductions in Unified Huntington’s Disease Rating Scale (UHDRS) Total Chorea Scores when the individual drugs were compared to placebo. Of note, Austedo XR was approved via a 505(b)(2) pathway using pharmacokinetic date from the Austedo IR FDA application, and there was no new clinical trial data available for review.

  - **Tardive dyskinesia:** A 2020 Journal of Clinical Psychiatry network meta-analysis evaluating data for Xenazine, Austedo IR, and Ingrezza suggested that VMAT2 inhibitors may be effective for tardive dyskinesia treatment. An additional 2017 network meta-analysis concluded Ingrezza and Austedo IR were promising but inconclusive, based on improvement in Abnormal Involuntary Movement Scale (AIMS) scores. Additionally, the network meta-analysis suggested a possible benefit for Xenazine for treating tardive dyskinesia symptoms but overall was rated as insufficient.

**Safety**

- In terms of safety, all agents carry similar warnings, including a black box warning for increased risk of depression and suicidal ideation in patients with Huntington’s disease. Multiple contraindications are listed for tetrabenazine (generic Xenazine) and Austedo, whereas Ingrezza only lists a contraindication for hypersensitivity. Overall, more sedation and extra-pyramidal symptoms are reported with tetrabenazine (generic Xenazine), while the rates of dry mouth and diarrhea are higher with Austedo IR and XR, and urticaria and rash are more common with Ingrezza.

**Individual Product Characteristics**

- **tetrabenazine (generic Xenazine):** Advantages include generic availability and long history of use. Although tetrabenazine does not carry a tardive dyskinesia indication, off-label use is widely accepted. Disadvantages include the lack of data regarding special populations, such as dosing adjustments for geriatric patients and those with renal failure, and the need for genotyping to identify possible drug interactions with CYPD26 metabolic variants. Multiple daily dosing is also required.

- **deutetetabenazine (Austedo IR and Austedo XR):** Both formulations are indicated for treating tardive dyskinesia, in addition to Huntington’s disease chorea. Austedo IR uniquely requires administration with food and multiple daily dosing.
Advantages of Austedo XR include once daily administration, however there is insufficient evidence at this time to determine what the average daily dosage requirement will be in terms of numbers of tablets required. Data regarding dosage adjustments in special populations is not available.

- **valbenazine (Ingrezza):** Advantages of Ingrezza include FDA-approval for both Huntington’s disease chorea and tardive dyskinesia, once daily dosing, and no requirement for dosage adjustment in geriatric patients or patients with renal failure.

**Clinical Coverage**

- At least one VMAT2 inhibitor is required on the formulary to meet the needs of the majority of MHS beneficiaries with either Huntington’s disease chorea or tardive dyskinesia.

**B. Neurological Agents Miscellaneous—Movement Disorders—Relative Cost-Effectiveness Analysis and Conclusion**

A CMA, BIA, and sensitivity analysis were performed. The P&T Committee concluded (19 for, 0 opposed, 0 abstained, 1 absent) the following:

- CMA results showed that within the Movement Disorder subclass, the generic formulation of tetrabenazine (Xenazine) is the most cost-effective agent.

- BIA was performed to evaluate the potential impact of designating the Movement Disorder subclass agents as UF, NF, or completely excluded from the formulary. BIA results showed that designating all agents as UF offered cost avoidance to the MHS.

**C. Neurological Agents Miscellaneous—Movement Disorders—UF Recommendation**

The P&T Committee recommended (19 for, 0 opposed, 0 abstained, 1 absent) the following:

- UF
  - tetrabenazine (generic Xenazine)
  - deutetetabenazine IR (Austedo IR)
  - deutetetabenazine ER (Austedo XR)
  - valbenazine (Ingrezza)
- NF - none
- Complete Exclusion - none

**D. Neurological Agents Miscellaneous—Movement Disorders—Manual PA Criteria**

Manual PA criteria have been in place for both Austedo and Ingrezza for several years, and for Austedo XR since the new drug review in August 2023. PA is not required for tetrabenazine. The P&T Committee recommended (19 for, 0 opposed, 0 abstained, 1 absent) minor updates to manual PA criteria for Austedo IR/XR and Ingrezza, in new users, primarily focusing on streamlining the safety monitoring requirements. For Huntington’s
disease chorea, the PA will still require a trial of generic tetrabenazine first, based on cost-effectiveness. There were no changes to the criteria for tardive dyskinesia.

The Manual PA criteria is as follows:

**deutetrabenazine immediate release (Austedo), deutetrabenazine extended-release (Austedo XR), valbenazine (Ingrezza)**

Changes from the November 2023 meeting are in bold and strikethrough

Manual PA criteria apply to all new users of Austedo IR, Austedo XR and Ingrezza

Manual PA Criteria: Coverage is approved for initial therapy for one year if all criteria are met:

- Patient does not have congenital or acquired long QT syndrome or arrhythmias associated with QT prolongation
- Patient does not have severe hepatic impairment
- Patient is not taking any of the following: MAOI within the past 14 days, reserpine, CYP3A4 inducers, or another VMAT2 inhibitor (e.g., tetrabenazine, deutetrabenazine [Austedo, Austedo XR], valbenazine [Ingrezza])
- Patient is 18 years of age or older
- Provider acknowledges the FDA safety alerts, boxed warnings, precautions, and drug interactions

**Huntington’s Disease Chorea**

- The drug is prescribed by or in consultation with a neurologist
- Patient has a diagnosis of chorea associated with Huntington’s Disease
- Patient does not have suicidal ideation
- Patient does not have depression or is being adequately treated for depression
- Patient has had an adequate trial of tetrabenazine for 12 weeks and has experienced treatment failure or experienced an adverse event that is not expected to occur with Austedo IR, Austedo XR or Ingrezza

**Tardive Dyskinesia**

- The patient is 18 years of age or older
- The drug is prescribed by or in consultation with a neurologist or psychiatrist
- Patient does not have suicidal ideation
- Patient does not have depression or is being adequately treated for depression
- Patient has moderate to severe tardive dyskinesia causing functional impairment along with schizophrenia, schizoaffective disorder, or a mood disorder
- Provider has considered a dose reduction, tapering, or discontinuation of the
dopamine receptor blocking agent suspected of causing the symptoms

Non-FDA-approved uses are NOT approved (e.g., Tourette's, dystonia)

PA expires in one year

Renewal Criteria: Note that initial TRICARE PA approval is required for renewal.
Coverage will be approved indefinitely for continuation of therapy if all criteria are met:
- Huntington’s Disease Chorea:
  - Patient has demonstrated improvement in symptoms based on clinician
    assessment
  - Patient is being monitored for depression and suicidal ideation
- Tardive Dyskinesia:
  - Patient has demonstrated improvement in symptoms based on an
    improvement of at least 2 on the Abnormal Involuntary Movement Scale
    (AIMS)
  - Patient is being monitored for depression and suicidal ideation

E. Neurological Agents Miscellaneous—Movement Disorders—UF and PA
Implementation Period

The P&T Committee recommended (19 for, 0 opposed, 0 abstained, 1 absent) an effective
date of the first Wednesday 30 days after the signing of the minutes in all points of service.

V. UF DRUG CLASS REVIEWS—NEUROLOGICAL AGENTS MISCELLANEOUS—
MOVEMENT DISORDERS

UF BAP Comments

A. Neurological Agents Miscellaneous—Movement Disorders—UF Recommendation

The P&T Committee recommended the following.

- UF
  - generic Xenazine
  - Austedo IR
  - Austedo XR
  - Ingrezza
- NF - none
• Complete Exclusion - none

**UF BAP Comments**

Concur: Non-Concur: Abstain: Absent:

---


The P&T Committee recommended Manual PA criteria as outlined above.

**UF BAP Comments**

Concur: Non-Concur: Abstain: Absent:

---

**C. Neurological Agents Miscellaneous—Movement Disorders—UF, PA, and Implementation Period**

The P&T Committee recommended the implementation plan of an effective date of the first Wednesday 30 days after the signing of the minutes as described above.

**UF BAP Comments**

Concur: Non-Concur: Abstain: Absent:

---

**VI. NEWLY APPROVED DRUGS PER 32 CFR 199.21(g)(5)**

**P&T Comments**

The products were divided into three groups when presented at the P&T Committee meeting. The generic names are provided below. Group 1 included the Humira biosimilars, Brenzavvy, Lodoco, Iyuzeh, Akeega, Suflave, Vanflyta, and Olpruva; Group 2 was comprised of Xdemvy, Ngenla, Opvee nasal, Sohonos, and Airsupra inhaler; and Group 3 included the coronavirus disease (COVID-19) drugs, Paxlovid and Lagevrio. Paxlovid was granted formal
FDA approval in May 2023, while Lagevrio is available under an Emergency Use Authorization (EUA).1

A. Newly Approved Drugs per 32 CFR 199.21(g)(5)—Relative Clinical Effectiveness and Relative Cost-Effectiveness Conclusions

The P&T Committee agreed (Group 1: 20 for, 0 opposed, 0 abstained, 0 absent; Group 2: 19 for, 0 opposed, 0 abstained, 1 absent; and Group 3: 19 for, 0 opposed, 0 abstained, 1 absent) with the relative clinical and cost-effectiveness analyses presented for the newly approved drugs reviewed according to 32 CFR 199.21(g)(5).

B. Newly Approved Drugs per 32 CFR 199.21(g)(5)—UF Recommendation

The P&T Committee recommended Group 1: 20 for, 0 opposed, 0 abstained, 0 absent; Group 2: 18 for, 0 opposed, 0 abstained, 2 absent; and Group 3: 19 for, 0 opposed, 0 abstained, 1 absent) the following:

- **UF**
  - nalmefene nasal spray (Opvee) – Alcohol Deterrents-Narcotic Antagonists
  - lotilaner 0.25% ophthalmic solution (Xdemvy) – Ophthalmic Anti-infectives
  - niraparib/abiraterone acetate (Akeega) – Oncological Agents
  - palvarotene (Sohonos) – Skeletal Muscle Relaxants and Combination
  - polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride powder for oral solution with flavor-enhancing packets (Suflave) – Laxatives-Cathartics-Stool Softeners: Bowel Preparations
  - quizartinib (Vanflyta) – Oncological Agent for Acute Myelogenous Leukemia (AML)
  - sodium phenylbutyrate packets for oral suspension (Olpruva) – Gastrointestinal-GI 2 Agents
  - nirmatrelvir/ritonavir (Paxlovid) – Antivirals for Coronavirus Disease (COVID-19)
  - molnupiravir (Lagevrio) Emergency Use Authorization – Antivirals for COVID-19

- **NF**
  - adalimumab (Humira) biosimilars–Targeted Immunomodulatory Biologics (TIBs)
    - adalimumab-adbm injection (Cyltezo)
    - adalimumab-fkip injection (Hulio)

---

1 Based on the FDA EUA status, this drug is technically not subject to 32 CFR 199.21(g)(5) and EUA drugs, in general, are not subject to automatic addition to the UF.
- adalimumab-fkip injection (unbranded biologic)
- adalimumab-aacf injection (Idacio)
- adalimumab-bwwd injection (Hadlima)
- adalimumab-aqvh injection (Yusimry)
- adalimumab-aaty injection (Yuflyma)
- adalimumab-adaz injection (Hyrimoz)
- adalimumab-adaz injection (unbranded biologic)
- albuterol and budesonide metered dose inhaler (Airsupra) – Short-Acting Beta Agonists (SABAs)
- bexagliflozin (Brenzavvy) – Diabetes Non-Insulin: Sodium-Glucose Code transporter 2 (SGLT2) Inhibitors
- latanoprost 0.005% ophthalmic solution (Iyuzeh) – Glaucoma Agents: Prostaglandin Analogs
- somatrogon-ghla injection (Ngenla) – Growth Stimulating Agents

**Complete Exclusion**
- colchicine 0.5 mg tabs (Lodoco) – Cardiovascular Agents Miscellaneous
  - Lodoco was recommended for complete exclusion as it has little to no clinical benefit relative to other colchicine formulations when used for cardiovascular risk prevention, and the needs of TRICARE beneficiaries are met by alternative agents. Formulary alternatives include colchicine 0.6 mg tablets (generic Colcrys) and 0.6 mg capsules (generic Mitigare).

**C. Newly Approved Drugs per 32 CFR 199.21(g)(5)—PA Criteria**

The P&T Committee recommended Group 1: 20 for, 0 opposed, 0 abstained, 0 absent; and Group 2: 18 for, 0 opposed, 0 abstained, 2 absent) the following PA criteria:

- Applying manual PA criteria to new users of Akeega, Iyuzeh, Sohonos, and Vanflyta.
- Applying manual PA criteria to new and current users of Xdemvy.
- Applying manual PA criteria to new users of the Humira biosimilars, similar to what is in place for the first Humira biosimilar, Amjevita. A trial of the Humira branded product is required first as per the February 2023 P&T Committee meeting minutes.
- Applying manual PA criteria to Brenzavvy, similar to what is in place for the other non-step-preferred SGLT2 Inhibitors. New patients receiving Brenzavvy or one of the other non-step-preferred SGLT2 Inhibitors (Farxiga, Invokana, Steglatro, or Inpefa) will require a trial of Jardiance first.
- Applying manual PA criteria to Ngenla, similar to what is in place for the other non-step-preferred growth stimulating agents. A trial of Norditropin, the step-preferred product is required first.
• Applying interim manual PA criteria for colchicine 0.5 mg tabs (Lodoco) prior to implementation of complete exclusion status, in order to minimize the impact on beneficiaries.

The Manual PA criteria is as follows:

1. **adalimumab-adbm injection (Cyltezo), adalimumab-fkip injection (Hulio), adalimumab-fkip injection unbranded biologic, adalimumab-aacf injection (Idacio), adalimumab-bwwd injection (Hadlima), adalimumab-aqvh injection (Yusimry), adalimumab-aaty injection (Yuflyma), adalimumab-adaz injection (Hyrimoz), adalimumab-adaz injection unbranded biologic**

Updates from November 2023 are in bold

Manual PA criteria apply to all new and current users of the Humira biosimilar

- The provider acknowledges that the originator adalimumab (Humira) is the preferred product over biosimilar adalimumab formulations
- The provider must provide patient specific justification as to why the originator Humira product cannot be used in this patient
  - Acceptable responses include that the patient has an allergy to an inactive ingredient found in the originator Humira that is not in the Humira biosimilar
- If the patient is younger than 18 years of age, coverage is provided for moderate to severe polyarticular juvenile idiopathic arthritis or moderate to severe Crohn's disease
  - If the indication is moderate to severe polyarticular juvenile idiopathic arthritis, patient must be 2 years of age or older
  - If the indication is moderate to severe Crohn’s disease patient must be 6 years of age or older
- If the patient is 18 years of age or older coverage is provided for moderately to severely active rheumatoid arthritis, moderate to severe Crohn’s disease, moderate to severe chronic plaque psoriasis where patient is candidate for systemic or phototherapy or when other systemic therapies are medically less appropriate, psoriatic arthritis, ankylosing spondylitis, moderate to severe ulcerative colitis, non-infectious uveitis, intermediate uveitis, posterior uveitis and panuveitis, and hidradenitis suppurativa
  - If the indication is moderate to severe chronic plaque psoriasis OR moderate to severe Crohn’s disease OR moderate to severe ulcerative colitis then patient must have had an inadequate response, intolerance, or contraindication to non-biologic systemic therapy. (For example: methotrexate, aminosalicylates [e.g., sulfasalazine, mesalamine], corticosteroids, immunosuppressants [e.g., azathioprine, cyclosporine], acitretin, or phototherapy), etc. unless they have fistulizing Crohn’s disease
• If the indication is ankylosing spondylitis has patient must have had inadequate response to at least two NSAIDs over a period of at least 2 months
• Patient has not had worsening congestive heart failure (CHF) and new onset CHF has not been reported with TNF blockers, including Humira
• Patient had evidence of negative TB test in the past 12 months (or TB is adequately managed)
• Patient is not receiving other targeted immunomodulatory biologics with Humira, including but not limited to the following: certolizumab (Cimzia), etanercept (Enbrel), golimumab (Simponi), infliximab (Remicade), apremilast (Otezla), ustekinumab (Stelara), abatacept (Orencia), anakinra (Kineret), tocilizumab (Actemra), tofacitinib (Xeljanz/Xeljanz XR), rituximab (Rituxan), secukinumab (Cosentyx), ixekizumab (Taltz), brodalumab (Siliq), sarilumab (Kevzara), guselkumab (Tremfya), baricitinib (Olumiant), tildrakizumab (Ilumya), risankizumab (Skyrizi), or upadacitinib (Rinvoq ER)

Non-FDA-approved uses are NOT approved, with the exception that if an indication is approved for Humira, it is approved for a biosimilar

PA does not expire

2. **bexagliflozin (Brenzavvy)**

Manual PA criteria apply to all new users of Brenzavvy
• The patient is 18 years of age or older
• Provider is aware and acknowledges that empagliflozin (Jardiance), empagliflozin/metformin (Synjardy, Synjardy XR) and empagliflozin/linagliptin (Glyxambi) are DoD’s preferred SGLT2 inhibitors, and that PA is not required for these drugs
• Brenzavvy is prescribed to improve glycemic control in patients with Type 2 Diabetes Mellitus
• Patient has experienced an inadequate response to metformin OR
• Patient has experienced a significant adverse effect to metformin OR
• Patient has a contraindication to metformin OR
• Patient has experienced significant adverse reactions to empagliflozin (Jardiance), empagliflozin/metformin (Synjardy, Synjardy XR) or empagliflozin/linagliptin (Glyxambi) OR
• Patient has a contraindication to empagliflozin (Jardiance), empagliflozin/metformin (Synjardy, Synjardy XR), or empagliflozin/linagliptin (Glyxambi)

Non-FDA-approved uses are not approved, including type 1 Diabetes Mellitus
PA does not expire
3. **colchicine 0.5 mg tabs (Lodoco)**

Interim Manual PA criteria apply to all users of Lodoco

- Provider acknowledges that Lodoco will be completely excluded from the TRICARE pharmacy benefit 120 days after the signing of these meeting minutes by the Director, DHA
- Provider acknowledges that other formulations of colchicine are available to TRICARE beneficiaries and do not require prior authorization including colchicine 0.6 mg tablets (generic Colcrys) and colchicine 0.6 mg capsules (generic Mitigare)
- Patient is 18 years of age or older
- Prescription is written by or in consultation with a cardiologist
- Patient has had a previous myocardial infarction or a history of an acute coronary syndrome, angina, history of stroke or transient ischemic attack, coronary artery disease, peripheral arterial disease or has undergone a coronary or other arterial revascularization procedure in the past.
- Patient is on guideline-directed standard therapies for the secondary prevention of cardiovascular events
- Patient has a creatinine clearance greater than or equal to 50 mL/min
- Patient does not have severe liver disease or pre-existing blood dyscrasias

Non-FDA-approved uses are NOT approved, including for gout, pericarditis, primary biliary cirrhosis, or periodic fever syndrome (must use the generic 0.6 mg formulations instead)

PA does not expire (until complete exclusion status implementation)

4. **latanoprost 0.005% ophthalmic solution (Iyuzeh)**

Manual PA criteria apply to all new users of Iyuzeh

- Iyuzeh is prescribed by an ophthalmologist or an optometrist
- Patient has a diagnosis of ocular hypertension or open-angle glaucoma
- Patient has had a trial of appropriate duration with two different formulary options, from any of the following glaucoma drug classes, in combination or separately:
  - prostaglandin analogs (e.g., Lumigan, Travatan, Xalatan)
  - beta blockers (e.g., Timoptic)
  - alpha2-adrenergic agonists (e.g., Alphagan P)
  - topical carbonic anhydrase inhibitors (e.g., Azopt, Trusopt, Cosopt)
- Patient has failed to reach intraocular target goals using medications from standard therapy classes (standard therapy classes include prostaglandin...
analogs, beta blockers, alpha2-adrenergic agonists, topical carbonic anhydrase inhibitors

- Patient is currently taking latanoprost and requires a preservative-free formulation due to experiencing adverse events OR
- Patient is on three or more different ocular medications that contain preservatives and accumulation of preservatives is a concern

Non-FDA-approved uses are NOT approved

PA does not expire

5. **niraparib and abiraterone acetate tabs (Akeega)**

Manual PA criteria apply to all new users of Akeega

- Patient is 18 years of age or older
- Akeega is prescribed by or in consultation with hematologist/oncologist or urologist
- Patient has deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC)
- Patient is using Akeega concurrently with a gonadotropin – releasing hormone (GnRH) analog (e.g., leuprolide, Eligard, Triptorelin, Goserelin) or has had a bilateral orchiectomy
- Akeega will be used in combination with prednisone

OR

- The diagnosis is NOT listed above but is cited in the National Comprehensive Cancer Network (NCCN) guidelines as a category 1, 2A, or 2B recommendation. If so, the provider must list the diagnosis.

AND

- Males with female partners will use effective contraception during treatment and for 4 months after the last dose
- Provider is aware of the warnings, screening and monitoring precautions for Akeega.

Other non-FDA-approved uses are NOT approved as noted above

PA does not expire

6. **lotilaner 0.25% ophthalmic solution (Xdemvy)**

Manual PA criteria apply to all new and current users of Xdemvy

- The patient is 18 years of age or older
- The drug is prescribed by an ophthalmologist or optometrist
• Patient has a diagnosis of Demodex blepharitis confirmed by the presence of Demodex mites on microscopic examination
• Patient has Demodex infestation with at least 10 eyelashes with collarettes
• Patient tried and failed an adequate treatment course with topical tea tree oil
• Patient will continue to practice good eyelid hygiene including eye lid wipes (e.g., Ocusoft)

Non-FDA-approved uses are NOT approved, including for dry eye disease or meibomian gland dysfunction

PA expires in 6 months; provider must fill out a new PA

7. palovarotene caps (Sohonos)

Manual PA criteria apply to all new users of Sohonos

• Female patients are 8 years of age and older
• Male patients are 10 years of age and older
• The drug is prescribed by a provider who specializes in the treatment of Fibrodysplasia Ossificans Progressiva
• Patient has a diagnosis of Fibrodysplasia Ossificans Progressiva confirmed with a genetic test
• Female patients of childbearing age are not pregnant as confirmed by (-) HCG prior to the first dose and then periodically during treatment
• Female patients of childbearing potential have been counseled to use effective contraception 1 month prior to treatment, during treatment and for 1 month after the cessation of therapy
• Pediatric patients with open epiphyseal plates will undergo assessments of skeletal maturity and linear growth prior to the first dose and every 6 to 12 months thereafter until reaching skeletal maturity or final adult height
• Provider is aware of the warnings, screening and monitoring precautions for Sohonos

Non-FDA-approved uses are not approved

PA expires in 1 year

Renewal Criteria: Note that initial TRICARE PA approval is required for renewal. Coverage will be approved indefinitely for continuation of therapy if all criteria are met:
• The patient has had a positive response to therapy
• The risks of continued therapy do not outweigh the benefits
8. **quizartinib tab (Vanflyta)**

   Manual PA criteria apply to all new users of Vanflyta
   
   - Patient is 18 years of age or older
   - The drug is prescribed by or in consultation with a hematologist/oncologist
   - Patient has newly diagnosed acute myeloid leukemia (AML) that is tyrosine kinase 3 (FLT3) internal tandem duplication (ITD)-positive as detected by an FDA-approved test
   - The provider is aware of all warnings, monitoring and screening precautions for Vanflyta
   - Provider is certified to prescribe Vanflyta per REMS requirements
   
   OR
   
   - The diagnosis is NOT listed above but is cited in the National Comprehensive Cancer Network (NCCN) guidelines as a category 1, 2A, or 2B recommendation. If so, the provider must list the diagnosis.

   Other non-FDA-approved uses are not approved

   PA does not expire

9. **somatrogon-ghla injection (Ngenla)**

   Manual PA criteria apply to all new users of Ngenla
   
   - Provider acknowledges that Norditropin is the Department of Defense’s preferred somatropin agent.
   - Patient is a pediatric patient between the ages of 3 to 17 years of age
   - Ngenla is being used for the indication of growth failure due to an inadequate secretion of endogenous growth hormone (GH) in pediatric patients
   - Ngenla is prescribed by or in consultation with a pediatric endocrinologist or nephrologist who recommends therapeutic intervention and will manage treatment
   - Patient has a contraindication to Norditropin OR
     - Patient has experienced an adverse reaction(s) to Norditropin, Omnitrope, AND Zomacton not expected with Ngenla AND
     - Patient requires a less than daily dosing regimen due to needle intolerance or aversion

   Non-FDA-approved uses are not approved, including Idiopathic Short Stature, normal aging process, obesity, and depression

   Coverage is not approved for concomitant use of multiple somatropin agents

   PA expires in 1 year; provider must fill out a new PA
D. Nalmefene Nasal Spray (Opvee) —Tier 1 Copay

The P&T Committee recommended (18 for, 0 opposed, 0 abstained, 2 absent) applying the Tier 1 (generic) copay for Opvee nasal spray per 32 CFR 199.21(e)(3)(iii). Other narcotic antagonists (i.e., naloxone) are also available at the Tier 1 copay. Availability of Opvee at the Tier 1 cost share will provide a greater incentive for beneficiaries to use a cost-effective narcotic reversal agent in the private sector points of service.

E. Newly Approved Drugs per 32 CFR 199.21(g)(5)—UF, PA, Opvee nasal spray Tier 1 copay and Implementation Period

The P&T Committee recommended (Group 1: 20 for, 0 opposed, 0 abstained, 0 absent; Group 2: 19 for, 0 opposed, 0 abstained, 1 absent; and Group 3: 19 for, 0 opposed, 0 abstained, 1 absent) an effective date of the following:

- **New Drugs Recommended for UF or NF Status and Opvee nasal spray Tier 1 copay**: an effective date of the first Wednesday two weeks after signing of the minutes.

- **New Drugs Recommended for Complete Exclusion Status**: 1) An effective date of the first Wednesday 120 days after signing of the minutes in all points of service, and 2) DHA send letters to beneficiaries who are affected by the complete exclusion recommendation at 30 days and 60 days prior to implementation.

- **New COVID-19 drugs Paxlovid and Lagevrio**: an effective date of no later than two weeks after signing of the minutes.

*Addendum to the UF recommendation – COVID Therapeutics*

**Tier 1 Copay for Paxlovid**: After the P&T Committee meeting, updated information was received regarding Paxlovid pricing for DoD. The new information was presented to the DoD P&T Committee members via electronic means. An electronic vote was obtained to recommend a Tier 1 copay for Paxlovid.

The P&T Committee recommended (17 for, 0 opposed, 0 abstained, 3 absent) applying the Tier 1 copay for Paxlovid, with implementation occurring no later than 2 weeks after signing of the minutes.

VII. NEWLY APPROVED DRUGS PER 32 CFR 199.21(g)(5)

*UF BAP Comments*

A. Newly Approved Drugs per 32 CFR 199.21(g)(5)—UF Recommendation

The P&T Committee recommended the formulary status for the newly approved drugs as discussed above.
• UF
  ▪ Opvee
  ▪ Xdemvy
  ▪ Akeega
  ▪ Sohonos
  ▪ Suflave
  ▪ Vanflyta
  ▪ Olpruva
  ▪ Paxlovid
  ▪ Lagevrio

• NF
  ▪ adalimumab (Humira) biosimilars–Targeted Immunomodulatory Biologics (TIBs)
    o Cyltezo
    o Hulio
      o unbranded biologic for Hulio
    o Idacio
    o Hadlima
    o Yusimry
    o Yuflyma
    o Hyrimoz
      o unbranded biologic for Hyrimoz
  ▪ Airsupra
  ▪ Brenzavvy
  ▪ Iyuzech
  ▪ Ngenla

• Complete Exclusion
  ▪ Lodoco

UF BAP Comments

Concur: Non-Concur: Abstain: Absent:
B. Newly Approved Drugs per 32 CFR 199.21(g)(5)—PA Criteria

The P&T Committee recommended the PA criteria for new drugs as stated previously.

**UF BAP Comments**

Concur:  Non-Concur:  Abstain:  Absent:

C. Newly Approved Drugs per 32 CFR 199.21(g)(5)—Opvee Nasal Spray Tier 1 Copay

The P&T recommended a Tier 1 copay for Opvee nasal spray, as stated previously.

**UF BAP Comments**

Concur:  Non-Concur:  Abstain:  Absent:

D. Newly Approved Drugs per 32 CFR 199.21(g)(5)—UF, PA, Opvee Tier 1 Copay, Paxlovid Tier 1 Copay, and Implementation Period

The P&T Committee recommended and effective date of the first Wednesday two weeks after the signing of the minutes for UF or NF status and the Tier 1 copay for Opvee nasal spray; 120 days after signing of the minutes for completely excluded status and an effective date of no later than two weeks after signing of the minutes for new COVID-19 drugs and Tier 1 copay for Paxlovid as outlined above.

**UF BAP Comments**

Concur:  Non-Concur:  Abstain:  Absent:

VIII. RE-EVALUATION OF NONFORMULARY GENERICS—PULMONARY-1 AGENTS AND CONTRACEPTIVES

**P&T Comments**
The DHA Pharmacy Operations Division (POD) Formulary Management Branch (FMB) monitors changes in clinical information, current costs, and utilization trends to determine whether the formulary status of NF drugs now available in generic formulations requires reassessment.

A. Re-Evaluation of Nonformulary Generics—Pulmonary-1 Agents: Short-Acting Beta Agonists (SABAs) and Combinations (Inhaled Corticosteroids/Long-Acting Beta Agonists – ICS/LABAs) Subclasses

The P&T Committee reviewed current utilization, formulary status, generic availability, and relative cost-effectiveness, including the weighted average cost per 30-day equivalent prescriptions for two NF Pulmonary-1 Agents, Symbicort and Proventil HFA.

1) Pulmonary-1 Agents: Combinations Subclass: budesonide/formoterol hydrofluoroalkane inhaler (Symbicort HFA)—At the February 2014 P&T Committee meeting, Symbicort was designated as NF, non-step-preferred, with PA requiring a trial of fluticasone/salmeterol (Advair) first. Subsequently the Symbicort manual PA criteria were updated in November 2019 to allow for acute use as a rescue therapy, based on clinical practice guidelines from the Global Initiative for Asthma (GINA) supporting ICS-formoterol over SABAs. The criteria were updated again in February 2021 to allow for intermittent and daily therapy, known as maintenance and reliever therapy or “MART”, based on the U.S. National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC) focused update to the Asthma Management Guidelines. Feedback from MTF providers supports moving Symbicort to UF status to expand beneficiary access to guideline-recommended MART treatment.

Generic formulations of Symbicort are now available, including the product labeled as Breyna and an authorized generic from Prasco. The cost of generic budesonide/formoterol HFA was compared to ICS/LABA formulary alternatives, including Advair Diskus, Advair HFA, and generic fluticasone/salmeterol diskus. The P&T Committee concluded that the weighted average cost per 30-day equivalent prescriptions for generic budesonide/formoterol HFA inhalers is within the range of other formulary options.

2) Pulmonary-1 Agents: SABAs: albuterol HFA 90 mcg (6.7 gram) inhaler (Proventil HFA)—The ProAir formulation (18 gram) of albuterol HFA inhaler was designated UF at the November 2013 P&T meeting, with other albuterol HFA inhalers designated as NF, including Proventil (6.7 gram) and Ventolin (8.5 gram). Step therapy does not apply to the class, since SABAs are used acutely for asthma and COPD symptoms.

Brand ProAir HFA has been discontinued from the market. There is now significant generic penetration into the SABA market basket, with availability of generic formulations for ProAir HFA, Proventil HFA and Ventolin HFA. The costs for the albuterol HFA inhalers and respective generics were evaluated. The P&T Committee concluded that the cost of generic Proventil HFA has decreased substantially and is
now similar to generic ProAir HFA. Moving Proventil to UF status will allow another rescue option for patients.

B. Re-Evaluation of Nonformulary Generics—Pulmonary-1 Agents—Formulary Status and Implementation

The P&T Committee recommended (20 for, 0 opposed, 0 abstained, 0 absent) the following, effective the first Wednesday 30 days after the signing of the minutes.

1) Pulmonary-1 Agents: Combinations: budesonide/formoterol HFA
   - Returning generic Symbicort HFA to UF status
   - Removing the budesonide/formoterol HFA PA criteria

2) Pulmonary-1 Agents: SABAs: albuterol HFA 90 mcg (6.7 gram), (Proventil HFA)
   - Returning generic Proventil HFA to UF status

C. Re-Evaluation of Nonformulary Generics—Contraceptives

The P&T Committee reviewed current utilization, formulary status, generic availability, and relative cost-effectiveness, including the weighted average cost per 28-day cycle, for the NF contraceptive products.

After comparison to similar agents on the UF, the P&T Committee agreed that seven products, including two chewable tablet formulations and two extended cycle products, should return to UF status. The P&T Committee noted that the two extended cycle products, which are packaged as 84 tablets containing active ingredients followed by 7 placebo tablets, are considered 3-month supply products. An 84-day supply of active drug would require the payment of 3 copays at retail. However, under existing “lesser-of” logic in place for retail network pharmacies for generic medications, patients pay the lesser of standard copays or the cost of the medication, sometimes resulting in total copayments for a 90-day supply that are less than the 30-day supply amount. Generic versions of these products have now dropped in cost below standard generic/Tier 1 copays. Patients would pay the standard generic/Tier 1 copay for a 3-month supply at mail order.

D. Re-Evaluation of Nonformulary Generics—Contraceptives—Formulary Status and Implementation

The P&T Committee recommended (19 for, 0 opposed, 1 abstained, 0 absent) returning the following generically available contraceptives products to UF status, effective the first Wednesday 2 weeks after the signing of the minutes.

- norethindrone 1 mg/ethinyl estradiol 20 mcg/iron (chew tab) (e.g., Charlotte 24 Fe, Finzala, Mibelas 24 Fe) – Generic Code Number (GCN) 34725
- norethindrone 1 mg/ethinyl estradiol 20 mcg/iron (e.g., Aurovela 24 Fe, Blisovi 24 Fe, Hailey 24 Fe, Junel Fe 24, Larin 24 Fe, Microgestin 24 Fe, Tarina 24 Fe) – GCN 26629
• norethindrone 0.8mg/ethinyl estradiol 25 mcg (chew tab) (e.g., Kaitlib Fe, Layolis Fe) – GCN 29719
• norethindrone 0.4mg/ethinyl estradiol 35 mcg (e.g., Balziva, Briellyn, Philith, Vyfemla) – GCN 11470
• norethindrone 0.4mg/ethinyl estradiol 35 mcg/iron (chew tab) (e.g., Wymzya Fe) – GCN 97167
• levonorgestrel 0.15 mg/ethinyl estradiol 30 mcg 3-month dose pack (e.g., Amethia, Ashlyna, Camrese, Daysee, Jaimiess, Simpessse) – GCN 27096
• levonorgestrel 0.1 mg/ethinyl estradiol 20 mcg 3-month dose pack (e.g., Camrese Lo, Lojaimiess) – GCN 18167

IX. RE-EVALUATION OF NONFORMULARY GENERICS—PULMONARY-1 AGENTS AND CONTRACEPTIVES

UF BAP Comments

A. Re-Evaluation of Nonformulary Generics—Pulmonary-1 Agents: ICS/LABAs, and SABAs—Formulary status and Implementation

The P&T Committee recommended returning generic Symbicort and generic Proventil HFA to UF status, and removing the PA for generic Symbicort, with implementation occurring 30 days after signing of the minutes, as outlined above.

UF BAP Comments

Concur:    Non-Concur:    Abstain:    Absent:

B. Re-Evaluation of Nonformulary Generics——Contraceptives—Formulary Status and Implementation

The P&T Committee recommended returning the seven contraceptives to UF status and an effective date of the Wednesday 2 weeks after the signing of the minutes as outlined above.

UF BAP Comments

Concur:    Non-Concur:    Abstain:    Absent:
X. UTILIZATION MANAGEMENT—PULMONARY-1 AGENTS—COMBINATIONS WITH INHALED CORTICOSTEROIDS/LONG-ACTING BETA AGONISTS (ICS/LABAs) AND INHALED CORTICOSTEROIDS (ICS)

P&T Comments

A. Pulmonary-1 Agents—ICS/LABAs

Background: Brand fluticasone/salmeterol (Advair Diskus and Advair HFA) have been the step-preferred ICS/LABA combination inhalers since the February 2014 drug class review. A generic formulation of fluticasone/salmeterol diskus (Wixela) was launched in January 2019. A trial of fluticasone/salmeterol is required before the NF non-step-preferred products, [budesonide/formoterol (Symbicort), mometasone/formoterol (Dulera), fluticasone/vilanterol (Breo Ellipta) and fluticasone/salmeterol respiclick (AirDuo Respiclick)] in patients 12 years of age and older. The generic (Tier 1 copay) applies to Advair Diskus, while Advair HFA has a Tier 2 copay. Authorized generic formulations of Advair HFA, Advair Diskus, Breo Ellipta and Symbicort are available; additionally, Advair Diskus and Symbicort also have multiple “traditional” generics.

Guidelines now recommend use of ICS-formoterol as both maintenance and reliever therapy (“MART”) for asthma symptom control; MART therapy does not apply to ICS combinations containing salmeterol.

Current step-therapy PA criteria were reviewed for the ICS/LABA combinations, due to the updated clinical practice guidelines, impending changes in availability for brand Advair HFA and Advair Diskus on December 31, 2023 (authorized generics by Prasco will remain available), and upcoming termination of current pricing agreements in January 2024.

The P&T Committee evaluated utilization trends and pricing for the ICS/LABA combinations. With the termination of current pricing agreements, Advair Diskus brand and Advair HFA brand will be less cost-effective, relative to other formulations.

B. Pulmonary-1 Agents—(ICS/LABAs—PA Criteria, Tier 1 Copay Removal, and Implementation

The P&T Committee recommended (20 for, 0 opposed, 0 abstained, 0 absent) the following, effective the first Wednesday 30 days after the signing of the minutes. There are no changes in the UF status for the ICS/LABA combinations, with the exception of Symbicort, which will move from NF to UF as noted in the NF Generic section.

- Advair Diskus brand:
  - Remove the Tier 1 copay and return to the Tier 2 copay
  - Will remain UF
  - Note that PA will not be required for generic fluticasone/salmeterol diskus (e.g., Wixela and other generics).
- Advair HFA brand and fluticasone/salmeterol HFA generics
  - Will remain UF
New PA criteria requiring a trial of the more cost-effective generic fluticasone/salmeterol diskus (e.g., Wixela and other generics) in new users older than 12 years of age. Providers will also acknowledge that PA is not required for Symbicort.

- **Dulera, Breo Ellipta, AirDuo Respliclick**

  Update the PA criteria for Dulera, Breo Ellipta and AirDuo Respliclick requiring a trial of the more cost-effective generic fluticasone/salmeterol diskus (e.g., Wixela and other generics, rather than brand Advair Diskus or brand Advair HFA) in new users older than 12 years of age. The current automated step for the Advair Diskus/HFA lookback will be removed. Providers will also acknowledge that PA is not required for Symbicort.

  - Will remain NF

- **budesonide/formoterol (Symbicort and generics)** - will move from NF to UF, and the PA will be removed.

The Manual PA criteria is as follows:

1. **fluticasone/salmeterol Diskus (Advair Diskus) and authorized generic fluticasone/salmeterol diskus**

   Manual PA criteria apply to all new users of fluticasone/salmeterol diskus (Advair Diskus) and authorized generic fluticasone/salmeterol diskus 12 years of age and older

   PA is not required in patients younger than 12 years of age

   **Manual PA Criteria:** Advair Diskus is approved if:

   - Provider acknowledges that generic fluticasone/salmeterol diskus (e.g., Wixela and other generics) and generic budesonide/formoterol (Symbicort) are available without requiring prior authorization and the provider should consider writing for generic fluticasone/salmeterol diskus or generic budesonide/formoterol instead.

   - Provider acknowledges that if the patient requires an hydrofluoroalkane (HFA) inhaler that generic budesonide/formoterol (Symbicort) is an HFA inhaler, and the provider should consider writing for generic budesonide/formoterol instead

   - Patient has experienced significant adverse effects from generic fluticasone/salmeterol diskus that is not expected to occur with brand Advair HFA

   - Patient has had an inadequate response to generic fluticasone/salmeterol diskus
Patient previously responded to Advair HFA and changing to fluticasone/salmeterol diskus would incur unacceptable risk

Non-FDA-approved uses are NOT approved
PA does not expire

2. mometasone/formoterol (Dulera), fluticasone/vilanterol (Breo Ellipta)

Changes from the November 2023 meeting are in bold and strikethrough. The previous automated step therapy has been removed

Manual PA criteria apply to all new users of Dulera or Breo Ellipta 12 years of age and older
PA is not required in patients younger than 12 years of age

Manual PA Criteria: Dulera or Breo Ellipta is approved if:

- Provider acknowledges that generic fluticasone/salmeterol diskus (e.g., Wixela) and budesonide/formoterol (Symbicort) are available without requiring prior authorization and the provider should consider writing for generic fluticasone/salmeterol diskus or generic budesonide/formoterol instead.
- Use of generic budesonide/formoterol (Symbicort) and generic fluticasone/salmeterol diskus (e.g., Wixela) formulary agents (Advair Diskus and Advair HFA) is contraindicated
- Patient has experienced significant adverse effects from generic budesonide/formoterol (Symbicort) and generic fluticasone/salmeterol diskus (e.g., Wixela) that is not expected to occur with Dulera the nonformulary ICS/LABA medication
- Formulary agents (Advair Diskus and Advair HFA) Use of generic budesonide/formoterol (Symbicort) and generic fluticasone/salmeterol diskus (e.g., Wixela) have resulted or are like to result in therapeutic failure
- Patient previously responded to Dulera nonformulary agent and changing to generic budesonide/formoterol (Symbicort) and generic fluticasone/salmeterol diskus (e.g., Wixela) a formulary agent (Advair Diskus and Advair HFA) would incur unacceptable risk
- The patient has asthma and requires rescue therapy or intermittent and daily ICS-LABA therapy with an ICS-formoterol combination and generic budesonide/formoterol is not an option. Note that this does not apply to Breo Ellipta

Non-FDA-approved uses are NOT approved
PA does not expire
3. **fluticasone/salmeterol respiclick (AirDuo Respliclick)**

Changes from the November 2023 meeting are in bold and strikethrough.

The previous automated step therapy has been removed

Manual PA criteria apply to all new users of AirDuo Respliclick 12 years of age and older

PA is not required in patients younger than 12 years of age

**Manual PA Criteria:** AirDuo Respliclick is approved if:

- Provider acknowledges that generic fluticasone/salmeterol diskus (e.g., Wixela) and generic budesonide/formoterol (Symbicort) are available without requiring prior authorization and the provider should consider writing for generic fluticasone/salmeterol diskus or generic budesonide/formoterol instead.

- Is the patient 12 years of age or older?

- The patient has a diagnosis of asthma

- The patient requires salmeterol as the long-acting beta agonist (LABA) and requires a lower salmeterol dose than found in AirDuo vs. **generic fluticasone/salmeterol diskus (e.g., Wixela)** Advair Diskus or Advair HFA.

- The patient requires fluticasone/salmeterol and cannot manipulate the generic fluticasone/salmeterol diskus (e.g., Wixela) Advair Diskus or Advair HFA metered dose inhaler devices.

Non-FDA-approved uses are NOT approved, **including for chronic obstructive pulmonary disease (COPD)**

PA does not expire

---

**C. Pulmonary-1 Agents: Inhaled Corticosteroids (ICS)—PA Criteria, Tier 1 Copay Removal, and Implementation**

Background: Both of the fluticasone formulations, Flovent Diskus and Flovent HFA, are the step-preferred ICS agents, dating back to the May 2014 class review. An authorized generic fluticasone HFA formulation entered the market in August 2022, and a brand over generic requirement for a trial of brand Flovent HFA or Flovent Diskus was required before dispensing of the generic fluticasone HFA. The generic (Tier 1) copay applies to both Flovent HFA and Flovent Diskus.

Current PA criteria, utilization trends, and costs were evaluated for the ICS inhalers, due to upcoming market withdrawal of branded Flovent HFA and Flovent Diskus on December 31, 2023, with subsequent termination of current pricing agreements in January 2024. As a result, brand Flovent Diskus, brand Flovent HFA and authorized generic fluticasone HFA will not be cost effective.
The P&T Committee recommended (20 for, 0 opposed, 0 abstained, 0 absent) the following, effective the first Wednesday 30 days after the signing of the minutes

- Flovent HFA
  - Remove Tier 1 copay and return to the Tier 2 copay
  - Will remain UF
  - Remove brand over generic preference for Flovent HFA (remove the current PA for generic fluticasone HFA requiring a trial of Flovent HFA first).

- Flovent Diskus
  - Remove Tier 1 copay and return to Tier 2 copay
  - Will remain UF

- Note that there are no changes to the PA for the NF, non-step-preferred ICS, as the subclass will be reviewed at an upcoming meeting.

XI. UTILIZATION MANAGEMENT—PULMONARY-1 AGENTS UTILIZATION MANAGEMENT—ICS/LABA AND ICS

**UF BAP Comments**

A. ICS/LABAs—PA, Tier 1 Copay Removal, and Implementation Plan

The P&T Committee recommended removing the Tier 1 copay for Advair Diskus; new PA criteria for Advair Diskus brand and generic inhalers; updated PAs for Dulera, Breo Ellipta and AirDuo Respiclick in new users; and an implementation plan of 30 days after signing of the minutes, as outlined above.

**UF BAP Comments**

Concur:  Non-Concur:  Abstain:  Absent:

B. ICS—PA, Tier 1 Copay Removal, Brand over Generic PA removal and Implementation Plan

The P&T Committee recommended removing the Tier 1 copay for Flovent Diskus and Flovent HFA and removing the brand over generic preference for Flovent HFA, with an implementation plan of 30 days after signing of the minutes.

**UF BAP Comments**

Concur:  Non-Concur:  Abstain:  Absent:
XII. UTILIZATION MANAGEMENT—UPDATED PA CRITERIA FOR NEW FDA-APPROVED INDICATIONS

P&T Comments

A. Updated PA Criteria for New FDA-Approved Indications

The P&T Committee recommended updates to the PA criteria for several drugs, due to new FDA-approved indications and expanded age ranges. The updated PA criteria outlined below will apply to new users.

1) Targeted Immunomodulatory Biologics (TIBs): Tumor Necrosis Factor (TNF) Inhibitors Agents—adalimumab-atto (Amjevita)—Amjevita is now indicated for the treatment of uveitis in adults, including non-infectious intermediate, posterior, and panuveitis. The manual PA criteria were updated to allow for this indication, with the criteria matching what is currently in place for Humira.

2) Metabolic Agents-Miscellaneous

- odevixibat (Bylvay)—Bylvay has a new indication for cholestatic pruritis in patients 12 months of age and older with Alagille syndrome. The manual PA criteria were updated to allow for this new indication without an age limitation.
- maralixibat (Livmarli)—The manual PA criteria were updated to reflect the new expanded age indication in children as young as 3 months old with cholestatic pruritus from Alagille syndrome.

3) Oncological Agents—dabrafenib (Tafinlar) and trametinib (Mekinist)—The manual PA criteria were updated to allow for use in pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.

4) Oncological Agents: Breast Cancer—talazoparib (Talzenna)—The manual PA criteria were updated to allow for Talzenna use in combination with Xtandi for the treatment of homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) in adults. In addition, the PA was updated to include conception and breastfeeding warnings similar to what is in place for other oncology agents.

B. Updated Manual PA Criteria and Implementation Period for New FDA-Approved Indications

The P&T Committee recommended (20 for, 0 opposed, 0 abstained, 0 absent) updates to the manual PA criteria for Amjevita, Bylvay, Livmarli, Mekinist, Tafinlar, and Talzenna in new users. Implementation will be effective the first Wednesday 60 days after the signing of the minutes.
XIII. UTILIZATION MANAGEMENT—UPDATED PA CRITERIA FOR NEW FDA-APPROVED INDICATIONS AND IMPLEMENTATION PLAN

UF BAP Comments

Updated PA Criteria for New FDA-Approved Indications and Implementation Plan

The P&T Committee recommended updates to the manual PA criteria for Amjevita, Bylvay, Livmarli, Mekinist, Tafinlar, and Talzenna in new users with an implementation date the first Wednesday 60 days after the signing of the minutes as stated above.

UF BAP Comments

Concur:  Non-Concur:   Abstain:  Absent:

XIV. UTILIZATION MANAGEMENT—UPDATED PA CRITERIA FOR REASONS OTHER THAN NEW INDICATIONS

P&T Comments

A. Updated PA Criteria for Reasons other than New Indications

1) Antipsychotics: Atypical—brexpiprazole (Rexulti)—Earlier this year, Rexulti received a new indication for treatment of agitation associated with dementia due to Alzheimer’s disease. It was previously approved for schizophrenia and as adjunctive therapy to antidepressants in major depressive disorder. Updated manual PA criteria were recommended for the new agitation indication based on provider feedback. The new PA criteria will require specialist prescribing, ruling out other causes of agitation, and trial and failure of non-pharmacologic methods first. The manual PA criteria for the other indications will remain unchanged.

2) Phosphodiesterase-5 (PDE-5) Inhibitors—tadalafil—The PDE-5 inhibitors for erectile dysfunction were last reviewed in November 2019. Since the review, generic sildenafil and generic tadalafil prices have dropped precipitously. MTF providers requested a re-review of the current tadalafil PA criteria. TRICARE policy precludes eliminating the PDE-5 inhibitor PA, as treatment of organic impotency is a covered benefit subject to all applicable provisions of 32 CFR 199.4, but impotence solely due to psychological or psychiatric reasons is not covered.

The current tadalafil manual PA requires a trial of sildenafil first, unless the patient has failed therapy, experienced an adverse event or has a contraindication to sildenafil. Tadalafil also is approved for benign prostatic hyperplasia (BPH) which requires use of an alpha blocker (alfuzosin or tamsulosin) first. Upon review of clinical and cost data, the following three edits were recommended: adding an age
and gender edit, to allow men 40 years and older to bypass the PA; removing the sildenafil step; and removing the BPH step requiring a trial of tamsulosin or alfuzosin.

3) Skeletal Muscle Relaxants and Combinations—baclofen oral solution (Ozobax), baclofen oral suspension (Fleqsuvy), and baclofen oral granules (Lyvispah)—Ozobax, Fleqsuvy, and Lyvispah are all alternate oral baclofen dosage formulations and are designated as NF. Current PA criteria restricts use to the sole FDA-approved indication for treatment of spasticity. An MTF oncologist requested allowing use for oncology patients experiencing hiccups as a side effect to their chemotherapy regimens. The PA was updated accordingly.

4) Gastrointestinal-2 Agents: Chronic Idiopathic Constipation/Constipation-predominant Irritable Bowel Syndrome (CIC/IBS-C)—linaclotide (Linzess) and lubiprostone (Amitiza)—The CIC/IBS-C class was last reviewed in November 2018. At that time, Linzess and Amitiza were designated as UF, and the PAs for both drugs required a trial of standard laxatives first. Annual PA resubmission was also required. At the May 2021 P&T meeting, PA criteria were updated for Amitiza requiring new users to try Linzess first. The PAs for both Linzess and Amitiza were re-reviewed due to changes in commercial practice and analysis of PA submission rates by Military Health System providers. Based on a review of available clinical and cost data, the Linzess and Amitiza PAs will now expire after the first year and then afterwards will be approved indefinitely, if renewal criteria are met. In addition, the requirement for a trial of Linzess first before Amitiza was removed.

B. Updated Manual PA Criteria and Implementation Period

The P&T Committee recommended (20 for, 0 opposed, 0 abstained, 0 absent) criteria updates to the manual PA criteria for Rexulti, tadalafil, Ozobax, Fleqsuvy, Lyvispah, Linzess, and Amitiza. Implementation will be effective the first Wednesday 60 days after signing of the minutes.

XV. UTILIZATION MANAGEMENT—UPDATED PA CRITERIA FOR REASONS OTHER THAN NEW INDICATIONS AND IMPLEMENTATION PLAN

UF BAP Comments

Updated PA Criteria for Reasons other than New FDA-Approved Indications and Implementation Plan

The P&T Committee recommended criteria updates to the manual PA criteria for Rexulti, tadalafil, Ozobax, Fleqsuvy, Lyvispah, Linzess, and Amitiza with an implementation date effective the first Wednesday 60 days after signing of the minutes.

UF BAP Comments

Concur: Non-Concur: Abstain: Absent:
XVI. BRAND OVER GENERIC PA AUTHORIZATION AND TIER 1 COPAY: PULMONARY-2 AGENTS: LONG-ACTING MUSCARINIC ANTAGONISTS (LAMAs): TIOTROPIUM (SPIRIVA) HANDIHALER

P&T Comments

A. Tiotropium (Spiriva) HandiHaler

Tiotropium dry powder inhaler (Spiriva) HandiHaler was reviewed for formulary status in February 2013 and designated as UF. AB-rated generic versions have entered the market; however, these generic products are less cost-effective compared to the branded agent. Therefore, dispensing of the branded Spiriva Handihaler will continue at all three points of service and the generic will only be available with PA (i.e., the reverse of the current brand to generic policy). The prescriber will provide patient specific justification as to why the brand cannot be used. The Tier 1 (generic) copayment will apply to brand Spiriva HandiHaler.

The Manual PA criteria is as follows:

generic tiotropium dry powder HandiHaler

Manual PA criteria apply to all new users of generic tiotropium dry powder HandiHaler.

Manual PA criteria: generic tiotropium dry powder HandiHaler is approved if all the following criteria are met:

- The provider acknowledges that Spiriva Respimat is the Department of Defense’s preferred long-acting muscarinic antagonist and does not require prior authorization and is available at the lowest (generic) copay.
- The provider must document a patient-specific reason as to why the patient requires Spiriva Handihaler and cannot use the Spiriva Respimat device. (blank write-in)
  - Acceptable responses include that the patient cannot activate and prime the Respimat device.
- In order to receive the generic tiotropium dry powder HandiHaler the provider must document why the patient requires the generic and not the brand Spiriva HandiHaler (blank write-in).
  - Acceptable responses include that the patient has had an adverse reaction to an excipient in brand Spiriva HandiHaler that would not be likely to occur with the generic tiotropium HandiHaler.

Non-FDA-approved uses are NOT approved

PA does not expire
B. Brand Over Generic Requirement, PA Criteria, Tier 1 Copay, and Implementation Period

The P&T Committee recommended (20 for, 0 opposed, 0 abstained, 0 absent) requiring brand Spiriva HandiHaler over the generic in all new users at all points of service, based on cost effectiveness.

The effective date will be no later than 30 days after the signing of the minutes. The “brand over generic” requirement will be removed administratively when it is no longer cost-effective compared to the AB-rated generics. Additionally, Spiriva HandiHaler will be added to the rapid response (“safety net”) program, which is included in the new TRICARE Pharmacy, 5th Generation (TPharm5) contract.

XVII. BRAND OVER GENERIC PA AUTHORIZATION AND TIER 1 COPAY: PULMONARY-2 AGENTS: LONG-ACTING MUSCARINIC ANTAGONISTS (LAMAs): TIOTROPIUM (SPIRIVA) HANDIHALER AND IMPLEMENTATION PLAN

UF BAP Comments

The P&T Committee recommended requiring brand Spiriva HandiHaler over the generic in all new users at all points of service based on cost effectiveness with an effective no later than 30 days after the signing of the minutes.

UF BAP Comments

Concur: Non-Concur: Abstain: Absent:

XVIII. OVER-THE-COUNTER (OTC) DRUG BENEFIT—PROGESTIN-ONLY CONTRACEPTIVES: NORGESTREL TABLETS (OPILL)

P&T Comments

In accordance with 10 U.S.C. 1074g(a)(2)(F), implemented by 32 CFR 199.21(h)(5), an OTC drug may be included on the UF upon the recommendation of the P&T Committee and approval of the Director, DHA, based on a finding that it is cost-effective and clinically effective, as compared with other drugs in the same therapeutic class of pharmaceutical agents. OTC drugs placed on the UF, in general, will be treated the same as generic drugs on the UF for purposes of availability in the MTF pharmacies, retail pharmacies, and the Mail Order pharmacy program and other requirements. However, upon the recommendation of the P&T Committee and approval of the Director, DHA, the requirement for the prescription may
be waived for a particular OTC drug for certain emergency care treatment situations. In addition, a special retail pharmacy copayment may be established under 32 CFR 199.21(i)(2)(xii) for OTC drugs specifically used in certain emergency care treatment situations.

A. Progestin-Only Contraceptive—OTC Opill:

The P&T Committee evaluated the clinical and cost-effectiveness of the first OTC oral contraceptive, norgestrel 0.075 mg (Opill), for UF addition. Norgestrel 0.075 mg (Ovrette) was previously a legend drug but was pulled from the market in 2005 for business reasons, not due to efficacy or safety concerns. Opill was FDA-approved in July 2023 for OTC use, with commercial launch planned for early 2024.

Opill is a progestin-only contraceptive pill (POP). Other POPs include norethindrone 0.35 mg which is UF and drospirenone 4 mg (Slynd) which is NF. POPs require strict adherence and administration at the same time each day for maximal efficacy. Opill has similar efficacy to other prescription oral contraceptives and greater efficacy than other OTC contraceptives (e.g., condoms and spermicides.) POPs have fewer contraindications than combined oral contraceptives which contain estrogen. POPs can be safely used in a wider population including women who have just given birth, are breastfeeding, or have a history of, or risk factors for venous thromboembolism.

Retail pricing for Opill was not available at the time of the P&T Committee review as the product was not yet commercially launched. A cost-analysis of other contraceptive agents including other POPs was presented. Price bands were established for Opill to define cost effectiveness and to determine formulary placement when pricing is released.

B. Progestin-Only Contraceptive—OTC Opill—UF Recommendation, Copay, Prescription Requirement, and Implementation Period

The P&T Committee recommended (18 for, 0 opposed, 2 abstained, 0 absent) the following:

- Adding OTC norgestrel 0.075 mg tablets (Opill) to the UF, contingent on retail pricing cost effectiveness. If Opill pricing is not cost effective, then the formulary recommendation will be brought back to the DoD P&T Committee for further consideration at a later date.

- A copay is required pursuant to 10 USC 1074g(a)(6)(A) and 32 CFR 199.21(h)(5)(ii).

- A prescription is required pursuant to 32 CFR 199.21(h)(5)(ii).

- Implementation plan of two weeks after signing of the minutes or, if OTC Opill has not launched when the minutes are signed, implementation will occur two weeks after market launch of OTC Opill at all points of service.

MHS provider feedback and opinions voiced by P&T Committee members were in support of waiving the copay and prescription requirement for Opill. In contrast to naloxone and the emergency contraceptive Plan B, Opill is not considered an emergency treatment, and the copay and prescription requirement cannot be waived.
Notably, over half of U.S. states allow pharmacist prescribing of contraceptives, which is a potential option for MHS beneficiaries to obtain Opill.

The P&T Committee recognizes the continued challenges with variations in standards of practice and prescribing rules that are solely under the control of the individual U.S. states. MTF healthcare professionals should work with their local credentialing/privileging authority for any questions they have.

XIX. OVER-THE-COUNTER (OTC) DRUG BENEFIT―PROGESTIN-ONLY CONTRACEPTIVES: NORGESTREL TABLETS (OPILL) UF RECOMMENDATION, COPAY, PRESCRIPTION REQUIREMENT AND IMPLEMENTATION PERIOD

UF BAP Comments

The P&T Committee recommended adding OTC norgestrel 0.075 mg tablets (Opill) to the UF, contingent on retail pricing cost effectiveness, with an implementation plan of two weeks after signing of the minutes or two weeks after market launch of OTC Opill at all points of service as outlined above.

UF BAP Comments

Concur: Non-Concur: Abstain: Absent:

XX. CONSIDERATIONS OF BETTER CARE, HEALTHIER PEOPLE AND SMARTER SPENDING

P&T Comments

In accordance with 10 U.S.C. 1074g(a)(10), as implemented in 32 CFR 199.21(e)(3)(i), the P&T Committee may recommend, and the Director may, after considering the comments and recommendations of the Beneficiary Advisory Panel, approve special uniform formulary actions to encourage use of pharmaceutical agents that provide the best clinical effectiveness to covered beneficiaries and DoD, including consideration of better care, healthier people, and smarter spending.

A. Contraceptives

- Segesterone acetate/ethinyl estradiol vaginal ring (Annovera) was reviewed as an innovator in November 2019. It is the second contraceptive vaginal ring in the U.S. and can be used for up to one year. Annovera is currently available as UF with a Tier 2 copay. It is cost-effective compared to other alternate dose formulations.
- Medroxyprogesterone acetate (Depo-subq Provera) is a SC contraceptive injection administered every 3 months. Depo-subq Provera is currently available as UF with a
Tier 2 copay. Depo-subq Provera is cost-effective and is similar in price to Depo-Provera which is available at a Tier 1 copay.

B. Tier 1 Copay and Implementation Period

The P&T Committee recommended (19 for, 0 opposed, 1 abstained, 0 absent) the following updates to the Tier 1. Implementation will be effective the first Wednesday 30 days after the signing of the minutes.

- Applying the Tier 1 copay at Mail/Retail for Annovera and Depo-subq Provera

XXI. CONSIDERATIONS OF BETTER CARE, HEALTHIER PEOPLE AND SMARTER SPENDING

UF BAP Comments

The P&T Committee recommended applying the Tier 1 copay to Annovera and Depo-subq Provera, as outlined above, with an implementation effective the first Wednesday 30 days after the signing of the minutes.

UF BAP Comments

Concur:       Non-Concur:       Abstain:       Absent: